Company Filing History:
3 out of 896 
2 out of 49 
Years Active: 2021-2024
Title: Norihisa Ohtake: Innovator in Cancer Detection
Introduction
Norihisa Ohtake is a prominent inventor based in Ayase, Japan. He has made significant contributions to the field of cancer detection, holding a total of 3 patents. His innovative methods aim to improve the accuracy and simplicity of cancer diagnosis.
Latest Patents
Ohtake's latest patents focus on methods for detecting various types of cancers. One of his inventions provides a method for detecting cancer in a simple and highly accurate manner. This method involves measuring the levels of intact growth and differentiation factor (GDF15) propeptide and its fragments in a sample. The cancers targeted by this method include stomach cancer, pancreatic cancer, colorectal cancer, lung cancer, breast cancer, and esophageal cancer. Additionally, he has developed a reagent that includes an antibody specifically recognizing GDF15 propeptide.
Another significant patent addresses the detection of castration-resistant prostate cancer (CRPC). This invention aims to provide a straightforward and accurate method for detecting CRPC by measuring the GDF15 propeptide levels in a sample. This method serves as a novel detection marker for identifying castration resistance in prostate cancer patients during or after endocrine therapy.
Career Highlights
Throughout his career, Ohtake has worked with notable organizations, including Tosoh Corporation and Yokohama City University. His experience in these institutions has contributed to his expertise in cancer research and detection technologies.
Collaborations
Ohtake has collaborated with several professionals in his field, including Shohei Myoba and Noriaki Arakawa. These collaborations have further enhanced his research and development efforts in cancer detection.
Conclusion
Norihisa Ohtake is a dedicated inventor whose work in cancer detection has the potential to significantly impact medical diagnostics. His innovative methods and collaborations reflect his commitment to advancing healthcare technology.